NCT00760981已完成1 期
A Pilot Study of Imatinib Mesylate in Steroid Refractory Chronic Graft Versus Host Disease
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- David Miklos
- 入组人数
- 15
- 试验地点
- 2
- 主要终点
- The frequency of adverse events graded according to the CTCAE will be the primary endpoint
研究概览
简要总结
To determine if subjects with steroid refractory cGVHD can tolerate imatinib mesylate and whether their cGVHD responds to imatinib mesylate.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
Imatinib
Experimental
200 mg orally daily and 400 mg orally daily for 4 weeks.
干预措施: Imatinib (Drug)
结局指标
主要结局
The frequency of adverse events graded according to the CTCAE will be the primary endpoint
时间窗: Subjects will be monitored at 1, 4, 8, 16, and 24 weeks.
次要结局
未报告次要终点
研究者
David Miklos
Assistant Professor of Medicine
Stanford University
研究点 (2)
Loading locations...
相似试验
已完成
2 期
Itacitinib for Low Risk GVHDLow Risk Acute Graft-versus-host DiseaseGraft-versus-host-diseaseGVHDNCT03846479John Levine70
尚未招募
4 期
Efficacy and Safety of Anti-CD25 rhMAb in the Treatment of Steroid-Refractory cGVHDcGVHDNCT06364319Peking University People's Hospital30
已完成
2 期
Treatment of Steroid Refractory Gastro-intestinal Acute GVHD afteR AllogeneiC HSCT With fEcal Microbiota tranSferFecal Microbiota TransplantationNCT03359980MaaT Pharma24
终止
2 期
Vismodegib in Treating Patients With Steroid-Refractory Chronic Graft-Versus-Host DiseaseChronic Graft Versus Host DiseaseNCT02337517National Cancer Institute (NCI)6
终止
2 期
Imatinib Mesylate and Mycophenolate Mofetil for Steroid-Refractory Sclerotic/Fibrotic cGVHD in ChildrenChronic Graft-versus-host DiseaseNCT01898377Seoul National University Hospital9